System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Epublish 7 citations

PubMed: 36619542 DOI: 10.3389/fendo.2022.1068199

Potential role of 25(OH)D insufficiency in the dysfunction of glycolipid metabolism and cognitive impairment in patients with T2DM.

Front Endocrinol (Lausanne) 13:1068199

Authors: Hui-Min Sun, Yue Yu, Xin-Ran Gao, Ya-Dong Wei, Chuan-Zong Qi, Meng-Die Ma, Dan-Dan Xu, Ya-Yun Xu, Jin-Fang Ge

Affiliations

  • School of Pharmacy, Anhui Medical University, Hefei, China. The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China.
  • School of Pharmacy, Anhui Medical University, Hefei, China. Department of Pharmacy, North district of The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. School of Public Health, Anhui Medical University, Hefei, China.

Abstract

Purpose

To investigate the changes of plasma 25(OH)D levels in type 2 diabetes mellitus (T2DM) patients and explore its role in the dysfunction of glucose and lipid metabolism and cognition.

Methods

One hundred and thirty-two T2DM patients were enrolled and the demographic and clinical data were collected. The plasma concentration of 25(OH)D was detected and the patients were divided into two groups including a Vitamin D insufficient (VDI) group and a normal VD group according to the clinical diagnostic criterial of VDI with the plasma 25(OH)D level less than 29 ng/mL. The glycolipid metabolic and routine blood biochemical indices were detected, the plasma concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), soluble myeloid soluble trigger receptor 1 (sTREM1) were measured. The cognitive function was assessed using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A). The depressive symptomatology was assessed using the Center for Epidemiological Survey Depression Scale (CES-D). Sleep quality was assessed using the Pittsburgh sleep quality index (PSQI).

Results

There were 70 T2DM patients with VDI (70/132, 53.03%) in this study. The plasma concentrations of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial blood glucose (PBG), IL-6, and sTREM1 were remarkably increased in T2DM patients with VDI as compared with that with the normal VD, accompanied with an elevated BRIEF-A scores. There was no significant difference between groups with regard to the indices of blood lipid, liver function, and scores in CES-D and PSQI. Moreover, results of Pearson correlation test showed that the plasma 25(OH)D levels were negatively correlated with HbA1c, FPG, PBG, CRP, IL-6, sTREM1, CES-D sum scores, and PSQI sum scores, but positively correlated with the plasma levels of Serum creatinine (Scr). Furthermore, result of Receiver Operating Characteristic (ROC) curve analysis showed a predictive role of VDI levels in discriminating T2DM patients with higher cognitive impairments, with the sensitivity and specificity being 62.12% and 62.12%, respectively.

Conclusion

VDI is harmful for T2DM patients with a significant relation with the hyperglycosemia and cognitive dysfunction.

MeSH

Diabetes Mellitus, Blood, Interleukin-6, Cognitive Dysfunction, Cognition Disorders, Cognition, Glycolipids, Plasma, Diabetes Mellitus, Type 2

Cited by